Rani Therapeutics (NASDAQ:RANI - Get Free Report ) had its price target boosted by BTIG Research from $7.00 to $14.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's price objective suggests a potential upside of 106.49% from the company's current price.
Get Rani Therapeutics alerts:
Sign Up
RANI has been the topic of a number of other research reports. Canaccord Genuity Group cut their target price on shares of Rani Therapeutics from $21.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 27th. Wedbush restated an "outperform" rating and issued a $8.00 target price on shares of Rani Therapeutics in a research note on Tuesday, February 6th. Finally, HC Wainwright increased their price objective on Rani Therapeutics from $12.00 to $13.00 and gave the stock a "buy" rating in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Rani Therapeutics has a consensus rating of "Buy" and an average target price of $12.20.
Check Out Our Latest Analysis on RANI
Rani Therapeutics Trading Down 5.2 % Shares of RANI stock traded down $0.37 during mid-day trading on Thursday, reaching $6.78. The stock had a trading volume of 224,477 shares, compared to its average volume of 128,419. The company has a current ratio of 6.36, a quick ratio of 6.36 and a debt-to-equity ratio of 0.96. The stock's 50-day moving average price is $4.73 and its two-hundred day moving average price is $3.53. The firm has a market capitalization of $340.08 million, a PE ratio of -5.10 and a beta of 0.33. Rani Therapeutics has a 52-week low of $1.82 and a 52-week high of $8.75.
Rani Therapeutics (NASDAQ:RANI - Get Free Report ) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04. Equities analysts expect that Rani Therapeutics will post -0.94 earnings per share for the current fiscal year.
About Rani Therapeutics (
Get Free Report )
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
